![]() |
市場調査レポート
商品コード
1642703
トラベルワクチン市場レポート:構成、疾患、地域別、2025年~2033年Travel Vaccines Market Report by Composition, Disease, and Region 2025-2033 |
||||||
カスタマイズ可能
|
トラベルワクチン市場レポート:構成、疾患、地域別、2025年~2033年 |
出版日: 2025年01月18日
発行: IMARC
ページ情報: 英文 129 Pages
納期: 2~3営業日
|
トラベルワクチンの世界市場規模は2024年に44億米ドルに達しました。IMARC Groupは、2025年から2033年にかけての成長率(CAGR)は9.36%で、2033年には100億米ドルに達すると予測しています。同市場は、エキゾチックで人里離れた旅行体験に対する需要の高まり、公衆衛生プログラムの一環として国民に無料の旅行予防接種を提供する政府の取り組み、疾病パターンの変化や新たな脅威の出現などにより、着実な成長を遂げています。
市場の成長と規模:同市場は力強い成長を遂げているが、これは海外旅行活動の増加に起因しています。また、旅行関連疾患に対する大衆の意識の高まりが市場の成長を後押ししています。
技術の進歩:より便利で効果的な製剤のイントロダクションなど、ワクチン開発における技術革新は、旅行者をより確実に保護します。
産業用途:トラベルワクチンは、様々な病気に対する予防を提供するため、レジャー・出張どちらの旅行者にとっても極めて重要です。
地理的動向:北米は、旅行中の健康と安全に重点を置いており、市場をリードしています。しかし、多様な目的地があり、海外からの旅行者が多い欧州が急成長市場として浮上しています。
競合情勢:市場の主要プレーヤーは戦略的イニシアティブに積極的に取り組んでいます。ワクチン・ポートフォリオの拡充、旅行関連の新たな健康リスクへの対応、既存のワクチンの効能強化のため、研究開発(R&D)活動に投資しています。
課題と機会:市場は、ワクチン接種のためらいや規制上のハードルといった課題に直面する一方で、ワクチンへのアクセスの拡大や特定地域に合わせたワクチンソリューションといった機会にも遭遇しています。
将来の展望:ワクチン製造の研究開発(R&D)が進んでおり、トラベルワクチン市場の将来は有望です。さらに、渡航前の相談にデジタルヘルスソリューションを採用することで、市場の成長が促進されると予想されます。
海外旅行の増加
世界中の大衆の間で海外旅行が増加していることが、市場の成長を支えています。世界化と旅行へのアクセスの利便性が高まるにつれ、世界各地で感染症にさらされるリスクが高まっています。旅行者は、ヘルスケアの水準や疾病の流行が異なる目的地に足を踏み入れるため、予防接種は極めて重要な予防措置となっています。この動向は、レジャー旅行、ビジネス旅行、海外留学の増加によってさらに後押しされています。さらに、エキゾチックで人里離れた旅行を体験したいという願望が、独特の健康リスクのある地域を探検する個人を導き、特殊なワクチンの必要性を強調しています。旅行中の健康予防に対する個人の意識の高まりは、海外旅行者向けのワクチンの重要性を際立たせており、市場の見通しは良好です。
政府の取り組みと規制
政府の取り組みと規制は、市場の牽引役として極めて重要な役割を果たしています。多くの国が、公衆衛生を守り、海外旅行による疾病の蔓延を防ぐことの重要性を認識しています。その結果、いくつかの国の行政機関は、渡航予防接種に関する厳しい規制や勧告を実施しています。これらの規制は、国境を出入りする旅行者、特に病気のリスクが知られている目的地への旅行者に対して、特定の予防接種を義務付けていることが多いです。世界保健機関(WHO)による国際保健規則(IHR)では、特定の国を訪れる旅行者に黄熱病の予防接種の証明を義務付けています。さらに、一部の政府は、公衆衛生プログラムの一環として、国民に旅行用の予防接種を補助または無料で提供しています。こうした規制や取り組みは、旅行者に法的要件を課すだけでなく、トラベルワクチンの必要性に対する認識を高め、市場の需要を牽引しています。
世界の疾病の発生と流行
世界の疾病の流行やパンデミックは、市場の牽引役として大きな影響を及ぼしています。こうした出来事は旅行者や政府を勇気づけ、海外旅行に伴う潜在的な健康リスクを浮き彫りにしています。このような流行に対応して、特定の地域で流行している特定の感染症から身を守るワクチンに対する需要が高まっています。疾病の流行やパンデミックは、ウイルスの蔓延を緩和し、安全な旅行を促進するワクチンの開発や配布につながっています。旅行者は、自分自身や他人を守るために予防接種の必要性をより強く意識するようになり、トラベルワクチンの普及につながっています。各国政府や国際保健機関も、アウトブレイクを予防・制御する重要な手段としてワクチンの重要性を強調し、渡航前にワクチン接種を受けるよう渡航者に奨励しています。
疾病パターンの変化と新たな脅威
疾病パターンのダイナミックな性質と新たな感染脅威の出現が、市場の成長を強化しています。感染症は静的なものではなく、進化し、変異し、新たな地域に広がっていく。このように刻々と変化する状況の中で、進化する病原体と闘うためのワクチンの継続的な研究開発(R&D)活動が必要とされています。ジカウイルスやエボラ出血熱のような疾病は、近年の旅行者にとって重大な懸念事項として浮上しており、これらの脅威に対処するための特定ワクチンの開発を促しています。このような疾病パターンの変化に対する意識は、情報へのアクセスの容易さとともに、旅に出る前に予防接種によって身を守ろうとする個人の行動を促しています。
The global travel vaccines market size reached USD 4.4 Billion in 2024. Looking forward, IMARC Group expects the market to reach USD 10.0 Billion by 2033, exhibiting a growth rate (CAGR) of 9.36% during 2025-2033. The market is experiencing steady growth driven by the escalating demand for exotic and off-the-beaten-path travel experiences, government initiatives to provide free travel vaccinations to their citizens as part of public health programs, and changing disease patterns and emerging threats.
Market Growth and Size: The market is witnessing strong growth, which can be attributed to increasing international travel activities. In addition, the rising awareness among the masses about travel-related diseases is bolstering the market growth.
Technological Advancements: Innovations in vaccine development, such as the introduction of more convenient and effective formulations, is ensuring better protection for travelers.
Industry Applications: Travel vaccines are crucial for both leisure and business travelers, as they offer protection against various diseases.
Geographical Trends: North America leads the market, on account of its strong emphasis on health and safety during travel. However, Europe is emerging as a fast-growing market, driven by its diverse range of destinations and a large number of international travelers.
Competitive Landscape: Key players in the market are actively engaged in strategic initiatives. They are investing in research and development (R&D) activities to expand their vaccine portfolios, addressing emerging travel-related health risks, and enhancing existing efficacy of vaccines.
Challenges and Opportunities: While the market faces challenges, such as vaccine hesitancy and regulatory hurdles, it also encounters opportunities in expanding vaccine accessibility and tailored vaccine solutions for specific regions.
Future Outlook: The future of the travel vaccines market looks promising, with ongoing research and development (R&D) activities in vaccine production. Moreover, the adoption of digital health solutions for pre-travel consultations is expected to propel the growth of the market.
Rising international travel
The increasing international travel among the masses around the world is supporting the growth of the market. As globalization and accessibility to travel are growing, the risk of exposure to infectious diseases in various parts of the world is rising. Travelers are venturing to destinations with varying healthcare standards and disease prevalence, making vaccinations a crucial precaution. This trend is further bolstered by the growth of leisure travel, business travel, and international students studying abroad. Moreover, the desire for exotic and off-the-beaten-path travel experiences is leading individuals to explore regions with unique health risks, emphasizing the need for specialized vaccines. The growing awareness among individuals about health precautions while traveling is underscoring the importance of vaccines for international travelers, which is offering a favorable market outlook.
Government initiatives and regulations
Government initiatives and regulations play a pivotal role in driving the market. Many countries are recognizing the importance of safeguarding public health and preventing the spread of diseases through international travel. As a result, governing agencies of several countries are implementing stringent regulations and recommendations regarding travel vaccinations. These regulations often mandate certain vaccinations for travelers entering or exiting their borders, especially for destinations with known disease risks. The International Health Regulations (IHR) by the World Health Organization (WHO) require proof of yellow fever vaccination for travelers visiting certain countries. Additionally, some governments offer subsidized or free travel vaccinations to their citizens as part of public health programs. These regulations and initiatives not only create a legal requirement for travelers but also raise awareness about the necessity of travel vaccines, driving demand in the market.
Global disease outbreaks and pandemics
Global disease outbreaks and pandemics have a profound impact on driving the market. These events are encouraging travelers and governments, highlighting the potential health risks associated with international travel. In response to such outbreaks, there is an escalating demand for vaccines that can protect against specific infectious diseases prevalent in certain regions. Disease outbreaks and pandemics are leading to the development and distribution of vaccines to mitigate the spread of the virus and facilitate safe travel. Travelers are becoming more conscious about the need for vaccinations to protect themselves and others, leading to greater adoption of travel vaccines. Governments and international health organizations also emphasize the importance of vaccines as a key tool in preventing and controlling outbreaks, encouraging travelers to be vaccinated before embarking on their journeys.
Changing disease patterns and emerging threats
The dynamic nature of disease patterns and the emergence of new infectious threats are strengthening the growth of the market. Infectious diseases are not static, they evolve, mutate, and spread to new regions. This ever-changing landscape necessitates ongoing research and development (R&D) activities of vaccines to combat evolving pathogens. Diseases like Zika virus and Ebola are emerging as significant concerns for travelers in recent years, prompting the development of specific vaccines to address these threats. This awareness of changing disease patterns, along with the ease of accessing information, is encouraging individuals to seek protection through vaccinations before embarking on their journeys.
Mono Vaccines
Combination Vaccines
Combination vaccines account for the majority of the market share
Combination vaccines offer the convenience of protecting against multiple diseases with a single injection. Popular combination vaccines include those that guard against hepatitis A and B, as well as typhoid. The primary advantage of combination vaccines is their efficiency in providing comprehensive protection, simplifying the vaccination process for travelers. This convenience is especially appealing to individuals who plan to visit regions with multiple disease risks, reducing the number of shots required. The combination vaccines segment is growing due to increased demand for streamlined vaccination regimens and improved compliance among travelers seeking a one-shot solution for their health needs.
Mono vaccines consist of individual vaccines targeting specific diseases. These vaccines are designed to provide protection against a single infectious agent, such as hepatitis A, hepatitis B, or typhoid. Mono vaccines are often recommended when travelers are visiting regions with a particularly high risk of one specific disease. They offer the advantage of targeted protection, allowing travelers to customize their vaccination regimen based on their destination and individual health needs.
Hepatitis A
DPT
Yellow Fever
Typhoid
Hepatitis B
Measles and Mumps
Rabies
Meningococcal
Varicella
Japanese Encephalitis
Others
Hepatitis A represents the leading market segment
Hepatitis A is a highly contagious viral infection that can be contracted through contaminated food or water, making it a significant concern for travelers. This segment includes vaccines that provide immunity against the hepatitis A virus. Due to its prevalence in many travel destinations, hepatitis A vaccination is recommended for individuals traveling to regions with inadequate sanitation and hygiene standards. The prominence of hepatitis A in the market reflects the widespread recognition of its risk and the importance of vaccination for the health and safety of travelers.
DPT vaccines, which protect against diphtheria, pertussis (whooping cough), and tetanus, are another important segment in the travel vaccines market. While these diseases are not exclusive to travel-related risks, they are included in some international vaccination recommendations. Tetanus can be a concern if travelers are exposed to contaminated wounds during their journeys. Therefore, DPT vaccines are essential for ensuring comprehensive protection against these preventable diseases, even when traveling.
Yellow fever vaccines target the prevention of yellow fever, a mosquito-borne viral disease prevalent in certain tropical regions. Travelers visiting countries in Africa and South America where yellow fever is endemic often require proof of vaccination for entry. The yellow fever segment in the travel vaccines market serves travelers who plan to explore these high-risk areas and need to adhere to international health regulations.
Typhoid vaccines are essential for travelers heading to regions with a higher risk of typhoid fever, often linked to contaminated food and water sources. These vaccines protect against Salmonella typhi, the bacterium responsible for typhoid fever. The typhoid segment addresses the specific health needs of travelers venturing to areas with suboptimal sanitation and hygiene conditions.
Hepatitis B vaccines are important for travelers who may engage in activities that carry an elevated risk of exposure to the hepatitis B virus, such as unprotected sexual contact or medical procedures involving needles. While hepatitis B is not exclusive to travel, these vaccines cater to the needs of individuals seeking protection against this virus while away from their home country.
Asia Pacific
North America
Europe
Middle East and Africa
Latin America
North America leads the market, accounting for the largest travel vaccines market share
The market research report has also provided a comprehensive analysis of all the major regional markets, which include North America, Europe, Asia Pacific, the Middle East and Africa, and Latin America. According to the report, North America accounted for the largest market share due to the high level of outbound international travel from the United States and Canada. The region has a strong emphasis on health and safety during travel, and travelers are well-informed about the importance of vaccinations. Additionally, government recommendations and regulations, including those set by the Centers for Disease Control and Prevention (CDC) in the United States, play a significant role in promoting the uptake of travel vaccines. North America also benefits from a well-established healthcare infrastructure and a robust pharmaceutical industry, making travel vaccines readily accessible to the population.
Europe is another substantial market for travel vaccines. With its diverse range of destinations and a large number of international travelers, European countries have a strong demand for travel vaccinations. The European Union is establishing guidelines for travelers, recommending vaccinations based on destination and health history. European travelers tend to be proactive in seeking pre-travel healthcare advice, contributing to the growth of the market in the region.
The Asia Pacific region is experiencing rapid growth in the market due to a rise in outbound tourism and business travel. As economies in the region are expanding, more individuals have the means and desire to explore international destinations. This is resulting in a heightened awareness of travel-related health risks, catalyzing the demand for travel vaccines. Moreover, some countries are becoming popular tourist destinations, leading to an increase in inbound travelers who also require vaccinations.
The Middle East and Africa region also contribute to the market. This segment is driven by both outbound tourism and inbound travelers, as the region hosts various cultural, religious, and business events. Vaccinations are often mandated for individuals traveling to Mecca for Hajj or Umrah, further propelling the market growth. In addition, the presence of diseases like yellow fever and malaria underscores the importance of vaccinations for travelers.
Latin America is another growing market for travel vaccines, driven by increasing outbound travel from countries like Brazil and Mexico. Travelers from these regions often explore destinations within South America, North America, and Europe, necessitating vaccinations for disease prevention.
Key players in the market are actively engaged in several strategic initiatives. They are investing in research and development (R&D) activities to expand their vaccine portfolios, addressing emerging travel-related health risks and enhancing existing efficacy of vaccines. These companies are also focusing on increasing their global distribution networks to ensure accessibility to travel vaccines in diverse regions. Furthermore, they collaborate with healthcare providers, government agencies, and international health organizations to promote vaccination awareness and education among travelers. Additionally, pharmaceutical firms are exploring innovative vaccine delivery methods, such as oral or patch-based vaccines, to improve convenience and compliance for travelers. Overall, key players are dedicated to advancing the field of travel vaccines to meet the evolving needs of global travelers effectively.
The market research report has provided a comprehensive analysis of the competitive landscape. Detailed profiles of all major companies have also been provided. Some of the key players in the market include:
GlaxoSmithKline Pharmaceuticals Limited
Sanofi Pasteur
Merck & Co., Inc.
Novartis AG
Pfizer Inc.
ALK-Abello A/S
Bavarian Nordic A/S
Crucell (Subsidiary of Johnson & Johnson)
CSL Limited
AstraZeneca PLC
Altimmune, Inc.
Abbott Laboratories
Hoffmann-La Roche, Inc.